Z. Motahari
Molecular Research Laboratory, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, P.O. Box 14155-6451: Iran
M. Etebary
Molecular Research Laboratory, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, P.O. Box 14155-6451: Iran
E. Azizi
Molecular Research Laboratory, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, P.O. Box 14155-6451: Iran
ABSTRACT
In the present study, resistant subline of human breast cancer T47D cells was isolated by stepwise exposure to increasing concentrations of TAM (10-8- 10-6 M). The subline that showed resistance to 10-6 M of TAM, named T47D/TAMR-6, was compared to the parental cells with respect to the growth characteristics, cross-resistance to Adriamycin (ADR) and P-gp expression. A significant increase in doubling time of the T47D/TAMR-6 cells was observed when compared to the parental T47D cells. This indicates a relatively slow growth rate pattern of the resistant cells. The T47D/TAMR-6 cells also showed cross-resistance to 1x10-8 M concentration of ADR. Immunocytochemical analysis using monoclonal antibody (C494; Dako-Denmark) against human P-gp and LSAB2 detection kit (Dako-Denmark) revealed a significant increase in P-gp level in resistant cells when compared to parental cells. Therefore, present results indicate that P-gp can play an important role in development of resistance to TAM and cross-resistance to ADR in the human breast cancer T47D cells.
PDF References
How to cite this article
Z. Motahari, M. Etebary and E. Azizi, 2005. Studying the Role of P-glycoprotein in Resistance to Tamoxifen in Humen Breast Cancer T47D Cells by Immunocytochemistry. International Journal of Pharmacology, 1: 112-117.
DOI: 10.3923/ijp.2005.112.117
URL: https://scialert.net/abstract/?doi=ijp.2005.112.117
DOI: 10.3923/ijp.2005.112.117
URL: https://scialert.net/abstract/?doi=ijp.2005.112.117
REFERENCES
- Brown, P.H. and S.M. Lippman, 2000. Chemoprevention of breast cancer. Breast Cancer Res. Treatment, 62: 1-17.
CrossRefDirect Link - Freedman, A.N., B.I. Graubard, S.R. Rao, W. McCaskill-Stevens, R. Ballard-Barbash and M.H. Gail, 2003. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J. Natl. Cancer Inst., 95: 526-532.
PubMed - Dorssers, L.C., S. van der Flier, A. Brinkman, T. van Agthoven and J. Veldscholte et al., 2001. Tamoxifen resistance in breast cancer. Drugs, 16: 1721-1733.
CrossRefPubMedDirect Link - Dixon, A.R., J. Bell, I.O. Ellis, C.W. Elston and R.W. Blamey, 1992. P-glycoprotein expression in locally advanced breast cancer treated by neoadjuvant chemotherapy. Br. J. Cancer, 66: 537-541.
Direct Link - Funato, T., H. Harigae, S. Abe and T. Sasaki, 2004. Assessment of drug resistance in acute myeloid leukemia. Expt. Rev. Mol. Diagnost., 4: 705-713.
CrossRefPubMedDirect Link - Ferry, D.R., H. Traunecker and D.J. Kerr, 1996. Clinical trials of P-glycoprotein reversal in solid tumors. Eur. J. Cancer, 32A: 1070-1081.
CrossRefPubMedDirect Link - Choi, S.U., B.H. Lee, K.H. Kim, E.J. Choi and S.H. Park et al., 1997. Novel multidrug-resistance modulators, KR-30026 and KR-30031, in cancer cells. Anticancer Res., 17: 4577-4582.
PubMedDirect Link - Choi, S.U., C.O. Lee, K.H. Kim, E.J. Choi and S.H. Park et al., 1998. Reversal of multidrug resistance by novel verapamil analogs in cancer cells. Anticancer Drugs, 9: 157-165.
Direct Link - Gouaze, V., J.Y. Yu, R.J. Bleicher, T.Y. Han and Y.Y. Liu et al., 2004. Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol. Cancer Ther., 3: 633-639.
Direct Link - Clarke, R., S. Currier and O. Kaplan et al., 1992. Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells. J. Natl. Cancer Inst., 84: 1506-1512.
CrossRefDirect Link - Van den berg, H.W., M. Lynch, J. Martin, J. Nelson, G.R. Dickson and A.D. Crockard, 1989. Characterization of a tamoxifen-resistant variant of the ZR-75-1 human breast cancer cell line (ZR-75-9a1) and stability of the resistant phenotype. Br. J. Cancer, 59: 522-526.
Direct Link - Wosikowski, K., D. Schuurhuis, G.J. Kops, M. Saceda and S.E. Bates, 1997. Altered gene expression in drug-resistant human breast cancer cells. Clin. Cancer Res., 3: 2405-2414.
Direct Link - Sipila, P.E., V.J. Wiebe, G.B. Hubbard, S.K. Koester and V.D. Emshoff et al., 1993. Prolonged tamoxifen exposure selects a breast cancer cell clone that is stable in vitro and in vivo. Eur. J. Cancer, 29A: 2138-2144.
Direct Link - Lonn, U., S. Lonn, U. Nylen and B. Stenkvis, 1992. Appearance and detection of multiple copies of the mdr-1 gene in clinical samples of mammary carcinoma. Int. J. Cancer, 51: 682-686.
Direct Link - Johnston, S.R.D., B.P. Haynes, I.E. Smith, M. Jarman, N.P. Sacks, S.R. Ebbs and M. Dowsett, 1993. Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet, 342: 1521-1522.
Direct Link - Wang, C.S., H. Larue, A. Fortin, G. Gariepy and B. Tetu, 1997. MDR-1 mRNA expression by RT-PCR in patients with primary breast cancer submitted to neoadjovant therapy. Breast Cancer Res. Treatment, 45: 63-74.
CrossRefDirect Link - Markel, D.E., S.A. Fuqua, S.M. Hill and W.L. McGuire, 1988. P-glycoprotein gene amplification or overexpression is not detected in clinical breast cancer specimens. Prog. Clin. Biol. Res., 276: 61-73.
Direct Link - Leonessa, F., M. Jacobson, B. Boyle, J. Lippman, M. McGarvey and R. Clarke, 1994. Effect of tamoxifen on the multidrug-resistant phenotype in human breast cancer cells: Isobologram, drug accumulation and MDR, 170,000 glycoprotein (gp170) binding studies. Cancer Res., 54: 441-447.
Direct Link - Kellen, J.A., A.C.H. Wong and A. Mirakian, 1992. Immunohisto-chemical determination of P-glycoprotein in a rat mammary tumor treated with tamoxifen. In vivo, 6: 541-544.
Direct Link